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In little more than a decade, the biologic importance and
clinical significance of keratin intermediate filaments in
epithelial cells has become very evident. Indeed, several
autosomal dominant (and less commonly, recessive) human
diseases involving mutated keratin genes have been
described (Irvine and McLean, 1999; Smith, 2003). From
such studies, the accumulating mutation databases provide
useful clinical information for predicting prognosis, optimiz-
ing genetic counseling, and, if clinically and ethically
appropriate, undertaking DNA-based prenatal diagnosis.
Delineation of the exact nature of the pathogenic mutations
also provides a basis for the development of suitable and
perhaps optimal approaches to gene therapy.
So what have we learned from naturally occurring keratin
gene mutations, for example in the basal keratinocyte
filament protein keratins 5 and 14? For a start, mutations in
the KRT5 and KRT14 genes result in the blistering skin
disease, epidermolysis bullosa simplex (EBS). Most cases
of EBS are autosomal dominant and, with few exceptions,
the molecular pathology involves missense mutations on
one KRT5 or KRT14 allele, leading to dominant-negative
interference and consequent disruption of the basal keratin
intermediate filament network. Furthermore, the actual site
of the amino acid substitution influences the degree of
filament perturbation and the resulting clinical phenotype.
For example, missense mutations in the helical end
domains are the most disruptive and underlie nearly all
cases of Dowling-Meara EBS. Nevertheless, there are also
important lessons to be gleaned from studies on the rare
recessive cases of EBS. Such patients may show a
complete loss of keratin 14 expression (with premature
termination codons on both KRT14 alleles), and they
therefore represent human ‘‘knockouts’’. Homozygous
individuals have a blistering skin disease phenotype, but
heterozygous carriers are typically clinically normal. These
observations suggest that truncated forms of keratin 14,
aside from those resulting from mutations close to the 30
end of the gene, do not significantly interfere with keratin
filament polymerization and that one normal KRT14 allele is
sufficient to provide a normally functioning intermediate
filament network. Conceptually, therefore, this indicates
that one putative approach to somatic gene therapy in
autosomal dominant EBS might be to invoke strategies
that ‘‘silence’’ the allele bearing the disruptive missense
mutation.
The rationale for this approach is supported by data from
an inducible mouse model of EBS (Cao et al, 2001), in which
locally induced blisters heal by re-epithelialization from the
adjacent uninduced skin and then never recur at the
originally traumatized site. This demonstrates that kerati-
nocytes with a normal keratin filament network have a clear
selective growth and survival advantage over those cells
expressing a dominant keratin missense mutation.
The story can now be advanced further from a report in
this issue of the JID (Smith et al, 2004). The authors were
investigating a patient with Dowling-Meara EBS. Clinically,
the affected 20-year-old individual’s skin disorder had
improved with passing years, although such findings often
appear to be quite common, and perhaps typical, for this
disorder. Nucleotide sequencing of lymphocyte-derived
genomic DNA identified a heterozygous missense mutation,
R125C, in KRT14 — the most commonly reported mutated
residue in this form of EBS. However, in subsequent
analysis of cultured keratinocytes from this patient, sequen-
cing of keratin 14 cDNA showed that the mutation R125C
was barely detectable. Moreover, sequencing of keratino-
cyte DNA, in contrast to lymphocyte DNA, revealed
evidence of a second mutation arising on the same
KRT14 allele harboring R125C. The extra mutation com-
prised a 1-base pair insertion, 242insG, sited upstream of
the missense mutation. This frameshift creates a premature
termination codon immediately downstream and therefore
effectively silences the dominant-negative allele. This is the
first example of ‘‘natural gene therapy’’ involving functional
rescue by an obliterative second mutation in the same gene
and makes an intriguing addition to the expanding
repertoire of mechanisms underlying revertant mosaicism
in human keratinocytes.
Initial insight into natural repair mechanisms in correcting
pathogenic mutations in keratinocytes was first highlighted
in 1997 (Jonkman et al, 1997). These authors described an
example of ‘‘mitotic gene conversion’’ in which a patient
with recessive loss-of-function mutations in the COL17A1
gene (resulting in non-Herlitz junctional EB) had several
areas of normal-appearing skin. The phenomenon of gene
conversion involves one allele converting the mutated
region of the other allele to wild-type sequence. Notably,
in this patient, blistering was prevented despite no more
than 50% of the keratinocytes being ‘‘corrected’’. Such
findings indicate that not all cells need to be reverted by
gene therapy to completely rescue and restore the normal
skin phenotype.
Subsequently, there have been a number of reports of
revertant mosaicism (in autosomal recessive genoderma-
toses) arising through various diverse mechanisms (for
review see Jonkman et al, 2003), including a remarkable
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frame-restoring mutation in the COL17A1 gene (Darling
et al, 1999). In that case, the pathogenic 2-base pair
deletion was ‘‘restored’’ by a compensatory downstream 2-
base pair insertion. Another example of revertant mosaicism
involved a patient with a homozygous splice site mutation in
KRT14 that resulted in numerous out-of-frame transcripts,
an absence of keratin 14 immunostaining and a phenotype
of recessive EBS (Schuilenga-Hut et al, 2002). However,
later skin biopsies showed focal re-expression of keratin 14,
and a new in-frame transcript that deleted two amino acids
and changed one other was identified. The mechanism
underlying this new finding was not elucidated, but it may
have involved a somatic extragenic second site mutation or,
more probably, modification through RNA editing (a rare
form of post-transcriptional processing). The latter view is
supported by data from a further unrelated patient with the
same keratin 14 splice site mutation (Jonkman et al, 2003).
It is becoming clear that whatever precise correction
mechanism of ‘‘natural gene therapy’’ is implicated, the
clinical relevance of the conversion process depends on
several factors. These include the number of cells involved
(although subsequent positive selection pressure is also
clearly relevant), how much reversal actually occurs, and at
what stage in life the reversion takes place (Jonkman et al,
2003).
Together, these factors determine the overall changes (if
any) in skin phenotype. But there are also lessons to be
learned that are relevant to the appropriate design of
‘‘artificial gene therapy’’, including therapy by gene editing
(chimeraplasty) and mRNA rescue. Furthermore, the im-
plications of an identifiable positive selection pressure for
reverted keratinocytes have relevance to cell therapy
approaches in general. Indeed, the new findings by Smith
et al and other related studies offer an intriguing possible
new insight into why the severity of skin disease in many
patients with autosomal dominant EBS may ameleiorate
with age. Clearly, further studies to investigate this hypoth-
esis are warranted, but nature is providing inherited skin
disease researchers with many clues about how best to fix
mutated structural protein genes in epithelial cells, and it
certainly pays to look, listen and learn.
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